Literature DB >> 29200325

Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.

Sarah B Whittle1, Kaitlin C Williamson2, Heidi V Russell1.   

Abstract

High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins with an induction phase comprised of intense multi-agent chemotherapy with the goal of maximally reducing tumor bulk. Given the high intensity of induction chemotherapy, neutropenic fever and infectious complications are common; however, the actual incidence is difficult to determine from clinical trial reports. We performed a retrospective review of infection-related complications in 76 children treated for high-risk neuroblastoma at Texas Children's Hospital. Medical records were reviewed for demographics, febrile neutropenia (FN) episodes, presence, and type of bacterial and fungal infections, and potential risk factors for infection. Fifty-seven percent of patients developed one or more serious bacterial or fungal infections during induction chemotherapy. Additionally, over 75% of patients had at least one admission for FN. Risk factors for developing any infection included female sex, MYCN amplification, and having Medicaid. Patients with external central venous catheters and those requiring parenteral nutrition had higher rates of bacteremia or fungemia. Each cycle, 50% were readmitted for either FN or infection. The overall burden of infectious complications was high, with 70% having two or more unplanned admissions for infection or FN. The incidence of febrile neutropenia and serious bacterial and fungal infections during induction chemotherapy for high-risk neuroblastoma is high. Most patients had at least two additional hospitalizations for infectious complications. Risk factors including female sex, MYCN amplification, payer status, and type of central access were associated with higher rates of infection in this cohort. ABBREVIATIONS: CLABSI Central line associated blood stream infection; CTCAE Common Terminology Criteria for Adverse Events; FN Febrile neutropenia; ANC Absolute neutrophil count; TPN Total parenteral nutrition.

Entities:  

Keywords:  Bacterial; chemotherapy; febrile neutropenia; fungal; infection; neuroblastoma

Mesh:

Substances:

Year:  2017        PMID: 29200325      PMCID: PMC7185719          DOI: 10.1080/08880018.2017.1396386

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  18 in total

1.  Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions.

Authors:  Lillian Sung; Richard Aplenc; Theo Zaoutis; Andreas H Groll; Brenda Gibson; Thomas Lehrnbecher
Journal:  Pediatr Blood Cancer       Date:  2008-10       Impact factor: 3.167

2.  Propensity score analysis confirms the independent effect of parenteral nutrition on the risk of central venous catheter-related bloodstream infection in oncological patients.

Authors:  Abdoulaye Touré; Cécile Chambrier; Philippe Vanhems; Catherine Lombard-Bohas; Jean-Christophe Souquet; René Ecochard
Journal:  Clin Nutr       Date:  2012-12-20       Impact factor: 7.324

3.  Association between urinary symptoms at 7 years old and previous urinary tract infection.

Authors:  A Hellström; E Hanson; S Hansson; K Hjälmås; U Jodal
Journal:  Arch Dis Child       Date:  1991-02       Impact factor: 3.791

4.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Authors:  K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

5.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

6.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Authors:  Susan G Kreissman; Robert C Seeger; Katherine K Matthay; Wendy B London; Richard Sposto; Stephan A Grupp; Daphne A Haas-Kogan; Michael P Laquaglia; Alice L Yu; Lisa Diller; Allen Buxton; Julie R Park; Susan L Cohn; John M Maris; C Patrick Reynolds; Judith G Villablanca
Journal:  Lancet Oncol       Date:  2013-07-25       Impact factor: 41.316

7.  Educating Families of Children Newly Diagnosed With Cancer.

Authors:  Maureen S Haugen; Wendy Landier; Belinda N Mandrell; Jeneane Sullivan; Courtney Schwartz; Micah A Skeens; Marilyn Hockenberry
Journal:  J Pediatr Oncol Nurs       Date:  2016-07-08       Impact factor: 1.636

8.  Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.

Authors:  Tamara P Miller; Yimei Li; Marko Kavcic; Andrea B Troxel; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Matt Hall; Marla H Daves; Terzah M Horton; Michael A Pulsipher; Jessica A Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Selina Luger; Alan S Gamis; Peter C Adamson; Richard Aplenc
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

9.  Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia.

Authors:  Lillian Sung; Alan Gamis; Todd A Alonzo; Allen Buxton; Kristen Britton; Joetta Deswarte-Wallace; William G Woods
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

10.  Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation.

Authors:  Thomas Lehrnbecher; Robert Phillips; Sarah Alexander; Frank Alvaro; Fabianne Carlesse; Brian Fisher; Hana Hakim; Maria Santolaya; Elio Castagnola; Bonnie L Davis; L Lee Dupuis; Faith Gibson; Andreas H Groll; Aditya Gaur; Ajay Gupta; Rejin Kebudi; Sérgio Petrilli; William J Steinbach; Milena Villarroel; Theoklis Zaoutis; Lillian Sung
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

View more
  4 in total

1.  Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.

Authors:  Sarah B Whittle; Valeria Smith; Allison Silverstein; Margaret Parmeter; Charles G Minard; M Brooke Bernhardt; Peter E Zage; Rajkumar Venkatramani; Jed G Nuchtern; Andras Heczey; Heidi V Russell; Jason M Shohet; Jennifer H Foster
Journal:  Pediatr Blood Cancer       Date:  2020-07-30       Impact factor: 3.167

2.  Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Heidi V Russell; Yueh-Yun Chi; M Fatih Okcu; M Brooke Bernhardt; Carlos Rodriguez-Galindo; Abha A Gupta; Douglas S Hawkins
Journal:  Cancer       Date:  2021-10-08       Impact factor: 6.860

3.  The human cathelicidin hCAP-18 in serum of children with haemato-oncological diseases.

Authors:  Natalja Jackmann; Sofia Englund; Per Frisk; Outi Mäkitie; Pauliina Utriainen; Anette Mörtberg; Birgitta Henriques-Normark; Katrin Pütsep; Arja Harila-Saari
Journal:  Br J Haematol       Date:  2022-07-18       Impact factor: 8.615

4.  Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2).

Authors:  Yangyang Cai; Yinghui Xu; Dongsheng Xu; Yizhuo Wang; Xu Wang; Chao Sun; Ye Guo; Shi Qiu; Kewei Ma
Journal:  Med Oncol       Date:  2020-08-03       Impact factor: 3.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.